Genetic Studies of Chronic Active Epstein-Barr Disease

Conditions

• Chronic Active Epstein-Barr Virus

Eligibility Criteria

Sex

ALL

Age

1 Year - 120 Years

Healthy Volunteers

Not accepted

Study Details

Epstein-Barr virus (EBV) is a member of the human herpes virus family that infects more than 95 percent of the U.S. population. Most infections occur in childhood and cause no symptoms; in adolescents and adults, EBV often causes infectious mononucleosis. It has also been associated with certain forms of cancer. Chronic Epstein-Barr virus (CAEBV) is a rare disease, primarily of children and young adults, that leads to life-threatening infections. This study seeks to identify genetic mutations responsible for CAEBV. A secondary goal is to learn more about the natural history of CAEBV. The study will examine blood and tissue samples from up to 50 patients (age 3 and above) with CAEBV and up to 150 of their relatives (age 1 and above). Autopsy samples may be included in the study. Up to 300 anonymous blood samples from the NIH Clinical Center Blood Transfusion Medicine will also be examined for comparison. No more than 450 milligrams (30 tablespoons) of blood per 8 weeks will be drawn from adult patients, and no more than 7 milliliters per kilogram of blood per 8 weeks will be drawn from patients under age 18. Local health care providers will refer patients to the study and will obtain the samples. Some patients may also be seen at the NIH Clinical Center. Those patients will have a full medical history and physical examination, along with chest X-ray, blood counts, blood chemistry, EBV serologies, and viral load. Other tests, such as CT scan or MRI, may be performed if medically indicated. Patients will be asked to undergo leukapheresis. In vitro tests on the blood or tissue samples will include analysis for proteins or genes that are involved in the immune response; cloning of portions of patient DNA; transformation of B cells with EBV; measurement of the ability of patient blood cells to kill EBV-infected cells; determination of lymphocyte subsets; and determination of antibodies to EBV or other herpes viruses. If a genetic cause for CAEBV is found, the investigators will be available to discuss the results with patients in person or by telephone. Genetic indications of risk for other diseases will also be discussed with patients.

Key Dates

Start date

Apr 16, 2002

Status verified

Apr 2026

Study Design

Enrollment

300 participants (estimated)

Arms

• Arm: CAEBV
  Patients with chronic active Epstein-Barr virus.
• Arm: Hydroa vaccineforme
  Patients with EBV hydro vaccineforme.

Primary Outcome Measure

The primary goal of this study is to identify genetic mutations responsible for CAEBV. [ Time Frame: ongoing ]

Central Contacts

• Jeffrey I Cohen, M.D.
  (301) 496-5265
  [email protected]

Locations (1)

Find similar trials in Bethesda, MD